Clinical trial · Observational
Glycosaminoglycan Scores as Early Detection Biomarkers in Bladder Urothelial Carcinoma
NCT05799456CI-TRIAL-00065331completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Early detection of bladder cancer (BCa) is considered an effective strategy to curb mortality from the disease. However, current urinary biomarkers have insufficient specificity to warrant BCa screening. Urine free glycosaminoglycan profiles (or GAGomes) are promising noninvasive biomarkers of cancer metabolism. In this study, samples are obtained from patients with BCa and controls to compare the glycosaminoglycan profiles between groups.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Free glycosaminoglycan profiling | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Bladder cancer
- interventionNames
- Diagnostic Test: Free glycosaminoglycan profiling
- label
- No evidence of disease
- interventionNames
- Diagnostic Test: Free glycosaminoglycan profiling
Primary outcomes (1)
- measure
- Area-under-the-receiving operating characteristic (ROC)-curve (AUC) for the classification of BCa versus NED
- timeFrame
- Before primary surgery for BCa; at a post-surgical follow-up visit for controls up to 5 years from primary surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Cases (Bladder cancer \[BCa\]) Inclusion Criteria: * Primary BCa diagnosis at cystoscopy, planned for TURB Exclusion Criteria: * No histopathological diagnosis of BCaTa-T4 N0-2 MX-0 after TURB Controls (No evidence of disease \[NED\]) Inclusion Criteria: * In follow-up with cystoscopy after treatment Ta-T3 N0-2 M0 BCa or upper tract urothelial cancer no evidence of disease at cystoscopy for at least 6 months prior to inclusion * No history of cancer except urothelial Exclusion Criteria: * Positive cytology at inclusion visit * Intravesical instillation therapy during 6 months prior to inclusion visit
References
Publications (0)
Data not yet available
No reference posted for this study.